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Background: The use of autologous blood concentrates, such as activated, concentrated platelets, in orthopaedic
clinical applications has had mixed results. Research on this topic has focused on growth factors and cytokines,
with little directed towards matrix metalloproteinases (MMPs) which are involved in post-wound tissue remodeling.
Methods: In this study, the authors measured the levels of MMP-2, MMP-9 and a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13 (ADAMTS13), in activated platelets derived from blood of healthy,
male volunteers (n = 92), 19 to 60 years old. The levels of the natural inhibitors of these proteases, tissue inhibitor of
metalloproteinase 1 (TIMP-1), TIMP-2 and TIMP-4 were also assessed.
Results: Notably, there was no significant change in concentration with age in four of six targets tested. However,
TIMP-2 and TIMP-4 demonstrated a statistically significant increase in concentration for subjects older than 30 years
of age compared to those 30 years and younger (P = 0.04 and P = 0.04, respectively).
Conclusion: TIMP-2 and TIMP-4 are global inhibitors of MMPs, including MMP-2 (Gelatinase A). MMP-2 targets
native collagens, gelatin and elastin to remodel the extracellular matrix during wound healing. A decreased
availability of pharmacologically active MMP-2 may diminish the effectiveness of the use of activated, concentrated
platelets from older patients, and may also contribute to longer healing times in this population.
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The use of activated, concentrated platelets, also known
as platelet-rich plasma (PRP), in orthopaedic therapies is
well studied. Current indications include treatment of
medial and lateral epicondylitis, tendinopathies, muscle
injuries, joint osteoarthritis, as well as for use intraoper-
atively with total joint arthroplasty to decrease blood
loss and narcotic requirements [1,2]. This therapy is a
simple tool that presumably harnesses the body's natural
healing pathways to promote faster repair of injured tis-
sue. However, the efficacy of these treatments has been* Correspondence: justin.m.hire.mil@mail.mil
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unless otherwise stated.debated [3-6]. Differences in the amounts and contents
of components in PRP depend on the preparation
method, and are also a function of human variability
[7,8]. Both preparation method and human variability
affect PRP efficacy, and this may perhaps explain the
mixed results observed in clinical trials [5]. Thus, more
consistent positive results may perhaps be achievable if
PRP use or dosage is optimized based on content, which
may be a function of factors like age or gender.
The concentration of growth factors and cytokines in
PRP are well described, some having correlations with
age [7,8]. However, the understanding of the dynamic
interplay between cell mediators remains incomplete
since matrix metalloproteases (MMPs) and tissue inhibi-
tors of metalloproteinases (TIMPs) are also found in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MMPs are known modulators of the extracellular matrix
through the cleavage of growth factor receptors, cause
the release of growth factors, independently affect the
extracellular matrix, and regulate all phases of wound
healing [9,10]. TIMPs affect tissue remodeling by inhibit-
ing MMPs in a 1:1 inhibitor-to-enzyme ratio but have
also been shown to have a direct biological effect on
multiple cell lines independent of inhibitor activity [10].
Little is known about the concentrations of MMPs and
TIMPs in PRP or how these might vary by age. A disin-
tegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 (ADAMTS13), although not an
MMP or TIMP, was included in this study due to recent
research that implicates this molecule in hemostasis and
wound healing [11]. This study was designed to deter-
mine the concentrations of MMPs and TIMPs in stan-
dardized, activated platelet concentrates and to correlate
these values with age, whole blood thrombocyte counts
and PRP thrombocyte counts.
Methods
Study design and sample collection
This study was approved by the Institutional Review
Board (IRB) at Dwight D. Eisenhower Army Medical
Center, Fort Gordon, GA. Blood samples were collected
from healthy individuals donating blood during routine
blood drives in collaboration with the Kendrick Memorial
Blood Donor Center (Fort Gordon, GA). All identifiable
subject information was omitted by study personnel.
Blood donors were provided with an information sheet be-
fore donating blood, which explained the purpose of the
study and allowed them to decline participation without
affecting their ability to donate blood. Blood samples from
a total of 92 males with a mean age of 34.4 ± 9.76 years
old (average ± SD, range 19–60) were collected. Only age,
gender, time of draw and time of PRP activation were
collected.
Isolation and activation of PRP
Citrated blood collection tubes (BD Biosciences, Franklin
Lakes, NJ, USA) were used to collect 8.5 mL of unused
blood from the diversion pouch of the blood donor bag
only after all tubes necessary for safety testing of do-
nated blood were collected. If 8.5 mL of blood was not
available, the tube was discarded and that sample was
not included in the study. The collected blood was then
drawn from the collection tube into an Arthrex autolo-
gous conditioned plasma (ACP) double syringe system
(Arthrex Systems, Naples, FL, USA) within 3 h of col-
lection and spun at 1,500 RPM for 5 min in a centrifu-
ge (Hettich Rotofix 32, Andreas Hettich GmbH & Co.,
Tuttlingen, Germany) as described by the manufacturer.
PRP was isolated and transferred to a 15-mL conicaltube. Aliquots of whole blood and PRP were measured
for red blood cell (RBC), white blood cell (WBC) and
platelet concentrations with a Coulter Ac T diff analyzer
(Beckman Coulter, Pasadena, CA, USA). The volume of
PRP collected was recorded and the PRP activated with
100 U bovine thrombin (Sigma-Aldrich, St. Louis, MO,
USA) in 10% calcium chloride (CaCl2) (Sigma-Aldrich,)
per mL PRP. A solid clot formed immediately. Then an
amount of sterile saline (Sigma-Aldrich, St. Louis, MO,
USA) equivalent to the volume of PRP collected for
each sample was added to the clot, and the clot was
gently disrupted to mix the components. After 90 min,
the remaining supernatant containing the released
MMPs and TIMPS were collected for future analyses.
Samples were immediately snap-frozen in liquid nitro-
gen and stored at −80°C. Aliquots were thawed once to
reduce MMP and TIMP degradation.MMP and TIMP quantification
A combination of six MMPs and TIMPs were individu-
ally analyzed by enzyme-linked immunosorbant assay
(ELISA; R&D Systems, Minneapolis, MN, USA). Matrix
metalloproteinase-2 (MMP-2), matrix metalloproteinase-
9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-
1), tissue inhibitor of metalloproteinase-2 (TIMP-2),
tissue inhibitor of metalloproteinase-4 (TIMP 4), and a
disintegrin and metalloproteinase with a thrombospon-
din type 1 motif, member 13 (ADAMTS13) were mea-
sured via manufacturer's recommendations. Standards
and samples were run in duplicate. Any value that was
below the limit of detection, based on a standard curve,
was assigned the lowest detectable value. This situation
occurred in three instances and is described in the ‘Results’
section below.MMP activity assay
The MMP activity level in each sample was determined
by fluorometric assay (Anaspec, Fremont, CA, USA). A
generic MMP substrate was utilized in the assay, in
order to measure total activity levels for MMPs gener-
ally, that included MMP-1, MMP-2, MMP-3, MMP-7,
MMP-8, MMP-9, MMP-12, and MMP-13. Not all of
these MMPs are released from platelets [12]. However,
this activity assay included the key MMPs being studied
and would give a more global perspective of overall
MMP activity present in the samples. Relative activity
(ra) was determined by measuring the difference be-
tween each sample compared to a blank. Eight samples
processed in the previous MMP/TIMP ELISA experi-
ments were omitted because of lack of sufficient sample
volume. The omitted samples included three from the
population of ≤30-year-olds, and five from the popula-
tion of >30-year-olds.
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Statistical analysis was performed in SPSS version 19.
Quantitative measurements were described with sum-
mary statistics (n, mean, standard deviation, median,
minimum, maximum, and other quantities). Intra-assay
variability was calculated to demonstrate the consistency
of results between duplicate samples with 1 being ideal.
Two-tailed correlation coefficients were calculated to
demonstrate relationships between age and MMP/TIMP
concentrations present in PRP (Pearson's correlation co-
efficient, rp). The study population was divided into two
study groups operationally defined based on a median
split (31.5 years). Rather than relying on the actual me-
dian, the median split was rounded down to 30 for ease
of interpretation. A series of multivariate tests were per-
formed with WBC as a covariate comparing subjects
older than 30 years of age and younger to those older
than 30 years. The null hypothesis for each test was
rejected at P ≤ 0.05.
Results
The platelet count from whole blood was 151 ± 35.3 ×
103/μL (mean ± SD). The platelet count from PRP was
248 ± 65.3 × 103/μl. Concentrations of MMPs and TIMPs
were found to vary widely (Table 1). Intra-assay variabil-
ity between duplicates was low with MMP-2 = 0.951,
MMP-9 = 0.870, ADAMTS13 = 0.968, TIMP-1 = 0.690,
TIMP-2 = 0.936, and TIMP-4 = 0.974. ADAMTS13 had
one sample below the detectable limit of 31.729 pg/mL
(age = 44 years old) and TIMP-4 had two samples below
the detectable limit of 262.78 pg/mL (ages = 21 and
51 years old). Neither of the later was from the same
sample as ADAMTS13.
The majority of targets demonstrated statistically sig-
nificant correlations with one another (Table 2). WBCTable 1 Descriptive statistical parameters
Age (years) MMP-2 MMP-9 T
(ng/mL) (ng/mL) (n
N 92 92 92 9
Mean 34.40 82.46 21.41 4
95% CI [32.28 to 36.42] [77.73–87.19] [17.57–25.25] [4
Median 31.50 78.50 16.81 4
SD 9.76 22.84 18.53 1
Minimum 20 15.30 7.69 1
Maximum 57 170.65 155.27 8
Percentile
10 23.00 60.32 10.09 3
25 26.00 68.80 11.96 3
75 42.75 92.46 23.80 5
90 49.70 110.41 34.63 6was not found to significantly correlate with any of the
other measures. TIMP-2 had an increased concentration
with age with linear regression analysis (rp 0.226, P =
0.025). TIMP-2 and TIMP-4 demonstrated statistically
significant increases for subjects over 30 years of age
compared with subjects 30 years of age and younger
(46.96 ± 10.85 ng/mL vs 41.80 ± 10.63 ng/mL, P = 0.04,
and 517.39 ± 149.64 ng/mL vs 451.04 ± 141.69 ng/mL,
P = 0.04, respectively) (Table 3). MMP-2, MMP-9,
ADAMTS13, and TIMP-1 displayed no significant differ-
ences in quantity with age (P > 0.05). Overall MMP
activity decreased with age (≤30-year-olds' average activi-
ty = 118 ra, 95% CI = 8.76 vs. >30-year-olds' average
activity = 110 ra, 95% CI = 6.96), but not enough to
achieve statistical significance by T test (P = 0.15).
Analysis of concentrations of metalloproteinases (MMPs)
and tissue inhibitor of metalloproteinases (TIMPs) as a
function of age between subjects aged over 30 years old
(>30) and subjects 30 years old and younger (≤30). Ana-
lysis performed with PRP WBC controlled for as a co-
variate; *Significant effects P < 0.05.
Discussion
The regulation of wound healing, the cleaving of growth
factor receptors, and the modification of the extracellu-
lar matrix are several functions of MMPs [9,10]. The
purpose of the present study was to assess variations of
MMPs and TIMPs from activated, concentrated platelets
from normal male blood donors. The major findings of
the study included a significant increase in TIMP-2 and
TIMP-4 concentrations for individuals aged over 30
compared to individuals 30 years of age and younger.
MMP-2, MMP-9, TIMP-1, and ADAMTS13 did not
demonstrate any statistically significant changes with
age. The shift in the MMP:TIMP balance could potentiallyIMP-1 TIMP-2 TIMP-4 ADAMTS13
g/mL) (ng/mL) (ng/mL) (pg/mL)
2 92 91 92
6.66 44.71 488.95 333.51
4.07–49.25] [42.44–46.99] [457.88–520.02] [312.55–354.47]
5.79 42.61 487.28 33.70
2.52 11.00 149.18 101.22
4.46 9.02 262.78 31.73
1.78 81.43 899.00 757.67
2.51 34.79 300.17 226.43
8.20 38.03 358.54 288.36
4.37 49.00 582.86 376.76
2.04 58.53 679.29 432.85
Table 2 Pearson's correlation coefficients for age, thrombocyte counts, and matrix metalloproteinases (MMPs)/tissue
inhibitor of metalloproteinases (TIMPs)
Age MMP-2 MMP-9 TIMP-1 TIMP-2 TIMP-4 ADAMTS13
MMP-2 n. s.
MMP-9 n. s. 0.282*
TIMP-1 n. s. 0.414* 0.326*
TIMP-2 0.226* 0.854* 0.261* 0.332*
TIMP-4 n. s. 0.550* 0.272* 0.256* 0.543*
ADAMTS13 n. s. 0.526* n. s. 0.425* 0.457* 0.309*
PRP WBC n. s. n. s. n. s. n. s. n. s. n. s. n.s.
*Significant correlation P < 0.05; n.s., not statistically significant.
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causing a decreased effectiveness of this modality in heal-
ing musculoskeletal pathologies as individuals age.
The use of concentrated, activated platelets or PRP re-
mains popular in the clinical and operative setting des-
pite mixed clinical results. Gardner et al. [1] performed a
retrospective analysis including 61 patients undergoing
total knee arthroplasty (TKA) with intraoperative use of
PRP and compared outcomes of pain, motion, blood
loss, and hospital stay to 37 control subjects. The PRP
group had less blood loss as measured by preoperative
and day 3 postoperative hemoglobin measurements (2.7-
g/dL vs. 3.2-g/dL decrease, P = 0.026), decreased narcotic
use while in hospital, achieved a higher range of motion
prior to discharge, and were discharged an average of
1 day earlier compared to the control group.Table 3 Analysis of MMP, TIMP, and ADAMTS13
concentrations in relation to age
Target age (years) Mean (SD) P value Power Effect size
MMP-2 0.08 0.42 0.04
≤ 30 77.56 (23.82)
> 30 86.23 (21.54)
MMP-9 0.11 0.28 0.02
≤ 30 18.24 (11.47)
> 30 23.85 (22.33)
TIMP-1 0.15 0.36 0.03
≤ 30 44.25 (12.04)
> 30 48.52 (12.67)
TIMP-2 0.04* 0.57 0.05
≤ 30 41.80 (10.63)
> 30 46.95 (10.85)
TIMP-4 0.04* 0.56 0.05
≤ 30 451.04 (141.69)
> 30 517.39 (149.64)
ADAMTS13 0.50 0.07 0.01
≤ 30 325.40 (118.51)
> 30 339.75 (86.32)Other studies for the therapeutic application of PRP
demonstrated sustained improvement of symptoms for
patients with lateral epicondylitis [13], decreased time to
resume training for athletes after open repair of the
Achilles tendon [14], and increased functional scores
and decreased pain after rotator cuff repair [15]. How-
ever, given the paucity of quality randomized controlled
trials on this subject, the benefits are called into ques-
tion upon further review by other authors. A meta-
analysis reviewed 15 randomized controlled trials and
five prospective cohort studies and found no clear clin-
ical benefit of PRP [5]. There was a trend of benefit fa-
voring PRP use, but this was not statistically significant
with wide confidence intervals. Varied clinical results
have necessitated further basic science investigations to
determine the optimal platelet concentration, prepar-
ation technique, and balance of cell signaling molecules
to aid healing.
The effect of PRP is likely not due to the action of a
single growth factor, cytokine, MMP, or TIMP, but in-
stead a sum of synergistic effects of these dynamic fac-
tors during tissue remodeling and healing [16]. MMPs
are involved in wound healing and pathological condi-
tions including osteoarthritis and rheumatoid arthritis
[17]. MMPs are proteases that degrade gelatin, collagen,
elastin, aggrecan, osteonectin, cytokines, growth factors,
and receptors [17]. These molecules establish chemotac-
tic gradients, regulate inflammation, and extravasation
of leukocytes into injured tissue [9]. MMP-9 (Gelatinase
B) is directly implicated in regulating inflammation by
modulating cell migration [9].
TIMPs have historically been thought of as inhibitors
of MMPs with varying affinities for specific MMPs
[9,17,18]. However, it has become clear that TIMP func-
tion may be more complex than previously estimated; in
some cases, a TIMP may actually activate an MMP. For
example, TIMP-2 activates MMP-2 (in complex with ac-
tive MMP-14) when it binds to the hemopexin-like do-
main of MMP-2 [19]. In contrast, TIMP-2 inhibits
MMP-2 when it binds to the catalytic site of MMP-2
[19]. TIMPs also affect cell proliferation independent of
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et al. [20] showed that MMPs and TIMPs likely induce
mesenchymal stem cells in response to mechanical force
at a fracture site. The authors argue that the balance of
MMPs and TIMPs is likely the deciding factor, as op-
posed to the individual activity of any single bioactive
molecule. Thus, these molecules must be considered to
grasp the overall effects of PRP activity. The selected
MMPs, TIMPs, and ADAMTS13 quantified in this study
were chosen as a representative sample of these classes
of molecules secondary to their release from platelets,
biological effects, and reproducible, cost-effective com-
mercial assays available to researchers.
The concomitant expression of MMPs and TIMPs has
been documented in gene studies [21]. The reason the
protease and its inhibitor are simultaneously induced is
for tight control of the extent of extracellular matrix
degradation and remodeling [18]. The correlation be-
tween MMP and TIMP concentrations in this study is
likely for the same reason, but further investigation con-
sidering the independent functions of these molecules
remains.
In this study, the authors observed a statistically sig-
nificant increase in TIMP-2 and TIMP-4 with age (P =
0.04 and P = 0.04, respectively). This shift of balance in
the protease:inhibitor ratio with age could alter overall
tissue remodeling potential. This issue is made even
more complex, given that TIMP-2 has multiple binding
sites on MMP-2, at least one of which is required first
for protease activation [19]. Only after activation, would
the inhibitory effects of TIMP-2 and other TIMPs tar-
gets be seen, via binding at the catalytic site. This mech-
anism of enzymatic activation by TIMPs, or pro-protein
convertases, is best known with the previous example,
but is presumed to occur for other MMPs as well [19].
The authors hypothesize that an increased TIMP-2 and
TIMP-4 concentration with age, as was demonstrated in
this study, would lead to a change in MMP: TIMP equi-
librium, causing an overall decrease of activity of the
MMP family. This effect would also impact growth fac-
tor activity, chemokine activity, and the inflammation
pathway. A decreasing trend in overall MMP activity
with age as measured using a generic MMP substrate
was observed. The cumulative effect of these compo-
nents may result in the decreased efficacy of this thera-
peutic modality as a function of age.
Limitations of this study include the in vitro analysis
of MMP and TIMP concentrations by ELISA. This is an
appropriate technique to quantitate these biomolecules
that would be given during therapeutic application of ac-
tivated, concentrated platelets, but does not measure ac-
tivity. No therapeutic intervention or patient outcome
was evaluated in this study design. Given the male dom-
inant military demographics of the donor population,insufficient female samples were collected to have ad-
equate power for further analysis. Further studies should
be conducted to include this population and perform
clinical studies in conjunction with PRP composition
analysis to correlate with patient outcome.
The selected biomarkers represent a small fraction of
all biologically active molecules released from platelets
and must be considered during interpretation of this
study. The platelet proteome variation is known to change
with advancing age [22]. Therefore, other changes in bio-
marker expression in addition to the findings in this study
may have a role in affecting healing. TIMP-1, TIMP-2,
and TIMP-4 are known to reside in distinct patches separ-
ate from the α-granule that contains many molecules in-
cluding Platelet Factor 4 (PF4), von Willebrand factor
(VWF), clotting factors, and growth factors [23,24]. The
kinematics of release from these separate storage areas
compared to the α-granule is not yet understood and
could be a confounding factor.Conclusions
MMPs and TIMPs act on biomolecules to regulate the
extracellular matrix during the tissue remodeling
process. In this study, TIMP-2 and TIMP-4 increased in
concentration with age (P = 0.04 and P = 0.04, respect-
ively) (Table 3). The overall change of the MMP:TIMP
equilibrium could impact the efficacy of PRP therapies.
Enhanced understanding of the concentration and bal-
ance of these molecules in PRP, coupled with the exist-
ing knowledge of growth factor and cytokine contents,
will better identify patients whose biology will favor
positive clinical results of this therapeutic modality. Fur-
ther clinical investigation is warranted to confirm these
laboratory findings.
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